N/A N=11 Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System
Type 1 Diabetes Mellitus
Primary: Hypoglycemic Events — 0.27; 1.0; 0.18; 0.18 events/patient
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Brain and Coordination Changes Induced By Robotics and FES Treatment Following Stroke
Cerebral Stroke · Cerebrovascular Accident · Stroke
Primary: AMAT — 1693; 1693; 1556; 1386 seconds
N/A N=328 The OMEGA Clinical Trial
Atherosclerosis · Coronary Artery Disease
Primary: 9-month Target Lesion Failure (TLF) Rate — 11.5 percentage of participants
N/A N=16 Effect of Oxytocin on Stress in Marijuana Users
Marijuana Dependence
Primary: Stress (as Measured by Cortisol) — 1.8; 2.1 nmol/L
Phase 3 N=700 A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in 0 to 24 Hour Weighted Mean Forced Expiratory Volume Over 1 Second (FEV1) at Day 84 — 0.213; 0.112 Liters — p=<0.001
Phase 2 N=117 Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)
Atherosclerosis · Myocardial Ischemia · Myocardial Infarction
Primary: Number of Participants Experiencing Adverse Events (AEs) Who Underwent Percutaneous Coronary Interventions (PCI) — 40; 30; 21 Participants
N/A N=12 Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker
Type 1 Diabetes Mellitus
Primary: Hypoglycemic Events — 0; 2; 1; 2 hypoglycemic events
N/A N=11 Prosthetic Components and Stability in Amputee Gait
Diabetes Mellitus · Leg Injuries · Traumatic Amputation
Primary: Local Dynamic Stability (Hip During Straight Walking) — .74; .74 dimensionless — p=>0.99
N/A N=1,262 Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Anemia · Breast Cancer · Cancer
Primary: Percentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL — 31.8 percentage of…
N/A N=464 ABC/Trident® Ceramic Post Approval Study
Arthroplasty, Replacement, Hip
Primary: Component Revision and Complications — 2; 2; 2 hips — p=0.0832
Phase 4 N=98 An Evaluation of the Effectiveness of Local Anesthetics Used During Intravenous Catheter Insertion
IV Insertion Pain
Primary: Differences in Patients' Perceptions of Pain Between Treatment Methods — 0.015; 0; 0; 1.909 units on a scale
N/A N=32 Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study
Diabetes Mellitus, Type 1
Primary: Percent Time Near Normoglycemia — 73; 52 percentage of time — p==0.037
Phase 4 N=465 Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
Meningococcal Disease
Primary: Percentages of Subjects With Persisting hSBA Titers ≥1:8 Against Neisseria Meningitidis (N. Meningitidis) Serogroups A, C, W and Y, Five Years After Having Received One…
Phase 3 N=150 Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
Postoperative Nausea and Vomiting
Primary: Proportion of Patients With no Emetic Episodes in the Overall Time Period 0-72 Hours Post-operatively — 88.0; 84.0 percentage of patients
Phase 2 N=54 Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder
Social Anxiety Disorder
Primary: Social Cooperation — 4.42; 4.69 Ball tosses